Podcast 46: Does Genetic Testing for Clotting Mutations Matter? An interview with Jodi Segal of Johns Hopkins

You’d think that a widely-ordered test would play a part in management and outcome, but two clotting mutations seem exceptions to that rule. Although often requested, the FDA-approved tests for Factor V Leiden and G20210A mutations don’t seem to figure greatly in case management of venous thromboembolism, at least according to the published literature. Dr. Jodi Segal and her team published a meta-analysis in JAMA this week, and she’s here to discuss the results. This week’s links: News– CDC Counsels Infection-Control Vigilance to Prevent H1N1 in Health Workers Zicam Nasal Cold Remedies Linked to Loss of Sense of Smell Stents Not Associated with Improved Function in Renal Artery Stenosis Leukotriene Modifiers for Asthma Associated with Neuropsychiatric Adverse Events Interview links– Does Testing for Clotting Mutations Improve Outcomes in VTE? Agency for Healthcare Research and Quality (AHRQ) The post Podcast 46: Does Genetic Testing for Clotting Mutations Matter? An interview with Jodi Segal of Johns Hopkins first appeared on Clinical Conversations.